Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-12-12 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺（庄学敏）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board. It details the candidate's qualifications, independence criteria, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report attachments. The document is a formal announcement related to board/management information, specifically about a director candidate's declaration and commitment. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not indicate it is a report or announcement of a report publication.
2023-12-12 Chinese
第四届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the convening and attendance of the fourth supervisory board's sixteenth meeting, including the approval of the 2023 third quarter report. The document references the actual third quarter report published separately on the Beijing Stock Exchange information disclosure platform, indicating this document is not the report itself but a meeting resolution about it. The document length is short (793 characters), and it serves as an official announcement of the meeting's decisions rather than containing substantive financial data or the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice.
2023-10-25 Chinese
第四届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 15th meeting of the 4th Board of Directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on the approval of the 2023 third quarter report. However, the actual third quarter report is not included in this document; instead, it references that the report was disclosed separately on the Beijing Stock Exchange information platform. The document is short (845 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2023-10-25 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 Third Quarter Report" of Guangdong Yongshun Biopharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period ending September 30, 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter and year-to-date periods. It is not an announcement of a report, nor a certification or a short summary. The length is substantial (15,000 characters), and the content is consistent with an Interim / Quarterly Report. Therefore, the document should be classified as an Interim / Quarterly Report (IR). 9M 2023
2023-10-25 Chinese
委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding the progress of entrusted financial management (委托理财进展的公告). It details the company's use of self-owned funds to purchase stable financial products, including amounts, expected yields, investment terms, and risk controls. The document includes disclosures required by the Beijing Stock Exchange listing rules about the scale of entrusted financial products relative to the company's audited net assets. It also describes internal controls and risk management related to these investments. There are no financial statements, earnings data, or comprehensive financial analysis present. The document is a regulatory disclosure about financing activities, specifically the use of company funds in financial products, which fits the category of Capital/Financing Update (CAP). The document length is about 4000 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2023-10-11 Chinese
投资者关系活动记录表
Regulatory Filings Classification · 95% confidence The document is an investor relations activity record from Guangdong Yongshun Biological Pharmaceutical Co., Ltd. It details a Q&A session held online with investors discussing the company's half-year performance, governance, strategy, and operational status. The document is short (1706 characters) and does not contain actual financial statements or detailed financial analysis. It is a record of an investor relations event rather than a formal financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2023-09-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.